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Abstract
Glioblastomas are highly aggressive brain tumors of adults with poor clinical outcome. Despite a broad range of new and
more specific treatment strategies, therapy of glioblastomas remains challenging and tumors relapse in all cases. Recent
work demonstrated that the posttranslational hypusine modification of the eukaryotic initiation factor 5A (eIF-5A) is a crucial
regulator of cell proliferation, differentiation and an important factor in tumor formation, progression and maintenance.
Here we report that eIF-5A as well as the hypusine-forming enzymes deoxyhypusine synthase (DHS) and deoxyhypusine
hydroxylase (DOHH) are highly overexpressed in glioblastoma patient samples. Importantly, targeting eIF-5A and its
hypusine modification with GC7, a specific DHS-inhibitor, showed a strong antiproliferative effect in glioblastoma cell lines
in vitro, while normal human astrocytes were not affected. Furthermore, we identified p53 dependent premature
senescence, a permanent cell cycle arrest, as the primary outcome in U87-MG cells after treatment with GC7. Strikingly,
combined treatment with clinically relevant alkylating agents and GC7 had an additive antiproliferative effect in
glioblastoma cell lines. In addition, stable knockdown of eIF-5A and DHS by short hairpin RNA (shRNA) could mimic the
antiproliferative effects of GC7. These findings suggest that pharmacological inhibition of eIF-5A may represent a novel
concept to treat glioblastomas and may help to substantially improve the clinical course of this tumor entity.
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Introduction
Gliomas are the most frequent primary brain tumors in adults.
As a result of diffuse infiltration, surgical resection of glioblastomas
(GBM) is difficult and the tumor usually relapses within months.
Adjuvant radiochemotherapy with alkylating agents like temozo-
lomide (TMZ), followed by cyclic TMZ therapy is able to delay
tumor progression and helps to increase the overall survival up to
14–15 months [1,2]. However, tumors become resistant to these
therapies e.g. by alterations in growth and survival signalling
pathways [3] or expression of DNA repair enzymes [4]. Based on
these observations, an extraordinary effort has been made to
identify novel therapeutic targets in GBM. In this context
a comprehensive list of tumor specific alterations were encoun-
tered using new sequencing technologies [5,6]. However, targeted
therapies directed against growth factor receptors, downstream
regulatory pathways or angiogenic capabilities of tumors by
tyrosine kinase inhibitors or monoclonal antibodies lacked efficacy
so far [7–10]. The disappointing results of current targeted
therapies in GBM and the frequent emergence of resistance
illustrates the urgent need for potential new molecular targets,
which would ideally be independent of the above-mentioned
mechanisms.
Here we present the highly specific posttranslational hypusine
modification of the eukaryotic initiation factor 5A (eIF-5A) as
a potential new target in glioblastoma. eIF-5A is a small acidic
protein carrying a unique post-translational modification termed
hypusine [11,12]. The synthesis of this unusual amino acid (a
spermidine dependent process termed hypusination) is carried out
in two subsequent steps by the enzymes deoxyhypusine synthase
(DHS) and deoxyhypusine hydroxylase (DOHH) at a conserved
lysine residue of eIF-5A and leads to an activation of the protein
[13]. In humans, two isofoms of eIF-5A, eIF-5A1 and eIF-5A2,
have been described [14,15]. Both isoforms have a high degree of
amino acid homology but a different pattern of tissue expression.
eIF-5A1 is ubiquitously expressed, whereas eIF-5A2 has been
detected mainly in the testis and in the brain [15]. Noteworthy, the
hypusine modification of eIF-5A is highly conserved in all
eukaryotes and in some archaea and seems to be essential for
the viability of eukaryotic cells [16]. The assumption is based on
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the observation that an inactivation of the hypusine formation is
lethal for yeast, mice and eukaryotic cell lines [17–19]. Although
eIF-5A was initially described as a translation initiation factor,
more recent studies have highlighted that eIF-5A has additional
cellular functions, including mRNA transport, binding of HIV
REV and HTLV-I REX transactivator proteins as well as
regulation of mRNA turnover [20,21]. Besides the well established
role of eIF-5A in proliferation and survival of eukaryotic cells, an
involvement in the regulation of apoptosis was brought into focus
(see [22,23] for comprehensive reviews). An role of hypusine
modification in the induction of apoptosis has been indicated by
Tome and Gerner [24,25]. They showed, that an excess
accumulation of the polyamine putrescine leads to a reduced
formation of hypusinated eIF-5A and apoptosis in DH23A/
b hepatoma cells. Caraglia et al. identified interferon-a (IFNa) as
a strong inducer of growth inhibition/apopstosis in human
epidermoid cancer KB cells. This observation was accompanied
by a strong inhibition of hypusine synthesis [26]. Interestingly, the
combination of IFNa and the DHS inhibitor GC7 had a synergistic
effect on the induction of cell growth inhibition and apoptosis in
those cells [27]. In our recent work we found eIF-5A to be
overexpressed in chronic myeloid leukemia patients and co-
treatment of BCR-ABL+ cells with imatinib and inhibitors of
hypusine synthesis yielded a synergistic effect [28]. Further, eIF-5A
and eIF-5A2 have already been associated with several other
malignancies in the past. eIF-5A was found to be overexpressed in
samples from colorectal adenoma and eIF-5A2 is present in
various cancer cell lines and its overexpression may serve as
a prognostic marker in patients with urothelial carcinoma or
ovarian cancer [29–31]. Additionally, eIF-5A and/or eIF-5A2
have been proposed as a transforming and predictive factor in the
development of hepatocellular carcinoma, non-small cell lung
cancer and in patients with ovarian carcinoma [32–34]. Recently,
Lu et al. reported that an ectopic expression of microRNA-7 leads
to a downregulation of eIF-5A and reduced cell migration,
invasion, and tumorigenesis in a glioma model [35]. Thus we
investigated the potential of eIF-5A and the hypusine forming
enzymes as possible novel targets for glioblastoma therapy.
We evaluated protein expression levels of eIF-5A1/2, DHS and
DOHH in 173 glioma tumor samples of different grades as well in
cell lines and analyzed the effect of inhibition of hypusination on
glioblastoma cells in vitro. We investigated the proliferation,
apoptosis and cell cycle in hypusination-impaired cells. Further,
we explored the effect of clinically used alkylating agents on
hypusine formation and potential additive antiproliferative effects
in combination with DHS inhibition.
Materials and Methods
Reagents
N1-Guanyl-1,7-diaminoheptane (GC7) was purchased from
Biosearch Technologies and was dissolved in sterile, millipore
filtered H2O to a final concentration of 10 mM. Bis-chloroethyl-
nitrosourea (BCNU, also known as Carmustine) and Temolozo-
mide (TMZ) were obtained from Sigma-Aldrich. BCNU was
dissolved in 50% EtOH at a concentration of 10 mM, whereas
TMZ was dissolved in DMSO at a concentration of 50 mM.
Cell Culture
Glioblastoma cell line G55T2 was already established from
primary tumour material previously, as described in [36,37]. U87-
MG cells were obtained from American Type Culture Collection
(Manassas, USA). Cell lines were maintained in Dulbecco’s
modified Eagle medium (DMEM)-high glucose + GlutamaxTM
supplemented with 10% FBS, 1 mM sodium pyruvate and
penicillin (50 U/ml)/streptomycin (50 mg/ml) (all from Invitro-
gen). Cells were passaged every 2–3 days. Because of their very
high proliferation rate, G55T2 cells were grown in said medium
with 5% FBS prior to cell cycle analysis. Primary normal human
astrocytes (NHA) were purchased from Invitrogen and cultivated
in DMEM-high glucose + GlutamaxTM supplemented with 20%
FBS, 1 mM sodium pyruvate and penicillin-streptomycin. All cell
lines were cultivated at 37uC in 100% humidity and 5% CO2 and
tested every few month for mycoplasma contamination.
Immunohistochemistry
Immunohistochemical detection of eIF-5A, eIF-5A2, DHS and
DOHH was performed on 4 mm sections of a tissue microarray
(TMA) and samples of normal human brain. The TMA comprised
30 pilocytic astrocytomas WHO grade I, 30 diffuse astrocytomas
WHO grade II, 27 anaplastic astrocytomas WHO grade III, 30
glioblastoma WHO grade IV, 28 oligodendrogliomas WHO grade
II and 28 anaplastic oligodendrogliomas WHO grade III. Samples
of normal brain were taken from two post mortems (female,
25 years of age: frontal, temporal and occipital cortex, thalamus,
basal ganglia, pons, brain stem, cerebellum, pituitary, Dura; male
89 years of age: frontal and temporal cortex, Pons, cerebellum),
a TMA containing tissue with neurodegenerative changes and one
cortical biopsy with neurodegenerative alterations (female,
67 years of age).
For labelling, an automated stainer (Ventana Medical Systems)
was used. The staining protocol comprised an antigen unmasking
step (microwave treatment for 1 hour), incubation with the
primary antibody for 30 minutes at 37uC (eIF-5A: rabbit mono-
clonal, Abcam ab32443, 1:100; eIF-5A2: mouse monoclonal
Abcam ab57421, 1:50; DHS: rabbit polyclonal, Santa Cruz SC-
67161, 1:50; DOHH: custom made antibody (Eurogentec; briefly,
rabbits were immunized with the following peptide:
QDTSQEPMVRHEAGEC. Polyclonal antibodies were affinity
purified against said peptide and provided in PBS with 0.01%
thimerosal and 0.1% BSA) 1:100, application of Ventana
horseradish peroxidase detection kit, visualisation of bound
antibodies with diaminobenzidine and counterstaining with
alum-hematoxylin.
Determination of staining intensity was performed in 4 grades
(0: none, 1: slight staining in up to 20% of cells, 2: moderate or
strong staining in up to 50% of cells, 3: moderate to strong staining
of .50% of cells) and only tumor cells were assessed. In normal
brain tissue all tissue components were evaluated for antigen
expression but staining intensities were not graded.
RNA Extraction and qPCR
RNA from cells was extracted with peqGOLD Trifast (Peqlab)
according to manufacturer’s instructions. After RNase treatment,
one microgram of RNA per sample was transcribed into cDNA
using M-MuLV reverse transcriptase (Fermentas) and 10 pmol
poly-A primer (Invitrogen) for 60 minutes at 37uC and 10 minutes
at 72uC.
The DyNAmoTM SYBRH Green qPCR Kit (Finnzymes) was
used for quantitative PCR in 20 ml reactions according to the
manufacturer’s instructions. Expression of human eIF-5A, -A2,
DHS and DOHH was analyzed with the respective predesigned
Quantitect primers (Qiagen, eIF-5A: QT00099911; eIF-5A2:
QT00031283; DHS: QT00013888; DOHH: QT00235536) with
RPLP0 (QT01839887) as housekeeping gene. One ml template
cDNA was used per reaction. Cycling conditions for PCR were:
95uC for 7 minutes and 35 cycles of 95uC for 10 seconds and
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60uC for 15 seconds. Relative expression was calculated using the
22DDCT method [38].
Western Blot
Cells were lysed with RIPA buffer complemented with protease
inhibitor cocktail (Sigma-Aldrich) and 25 mM Na3VO4. After lysis
for 10 minutes on ice, debris were pelleted by centrifugation at
210006g and lysates were stored at 280uC. Western blotting was
performed as described previously [28]. In brief, membranes were
incubated with anti-eIF-5A antibody (Novus Biologicals) diluted
1:5000 in 3% BSA, anti-DHS (Santa Cruz) 1:500 in 16RotiBlock
(Roth) and anti-DOHH (Eurogentec) 1:1000 in 5% skim milk
(Roth) over night at 4uC. Anti-p53 (Santa Cruz), p21Waf1/Cip1,
phospho-AKT (Ser473), AKT antibodies (Cell Signaling Tech-
nology) were diluted 1:1000 in 5% BSA and applied to the
membrane for one hour or overnight. Membranes were incubated
with an anti-b-tubulin antibody (Oncogene, 1:10000 in 3% BSA)
for one hour as loading control. After washing, the membranes
were incubated with anti-rabbit- (Cell Signaling Technology) or
anti-mouse-HRP (Sigma-Aldrich) antibody (1:10000 in PBST) for
one hour. Aceglow chemiluminescence reagent (Peqlab) was used
for visualization and images were collected with a CCD camera
system (FUSION SLTM, Peqlab). Membranes were stripped with
RestoreTM Western Blot Stripping Buffer (Thermo Scientific),
washed and reprobed as described above. Hypusinated and non-
hypusinated eIF-5A were detected by 2-dimensional-Western blots
[39]. For this purpose, 25 mg of protein were diluted ad. 120 ml in
urea lysis buffer (9 M urea, 4% CHAPS, 0.5% Resolyte [BDH
Biochemicals, Poole, United Kingdom], 10 mg/ml bromophenol
blue). First dimension IPG strips (7 cm, pH 7–14, GE Healthcare)
were rehydrated with the protein solution overnight. Isoelectric
focusing was carried out with the following parameters: 30 min-
utes at 500 V, 5000 Vh linear focussing at 5000 V followed by
5000 Vh ‘‘rapid’’ focussing at 5000 V and up to two hours storage
at 500 V.
After focusing, IPG strips were equilibrated for 2615 minutes in
6 M urea, 4% SDS, 50 mM Tris-HCl, pH 8.8, containing 1%
DTT for the first or 4.8% iodoacetamide for the second period of
equilibration. For the second dimension, samples were separated
on a 12% SDS-PAGE and an anti-eIF-5A Western blot was
performed as described above.
Cell Proliferation Assay
G55T2 and U87-MG cell lines were seeded at 46104 cells/well
in a 12-well plate. After 12 hours, GC7, TMZ or BCNU were
added and cells were incubated for 48 or 72 hours. The maximum
volume of vehicle (H2O for GC7, DMSO for TMZ and 50%
EtOH for BCNU) served as vehicle control. Cells were harvested
by trypsination with 300 ml trypsin/well followed by addition of
300 ml growth medium. The total volume was used for automated
cell counting/viability analysis by trypan blue exclusion with a Vi-
CELL Cell Viability Analyzers (Beckman Coulter).
3H-Spermidin Incorporation Assay
eIF-5A and eIF-5A2 are the only known proteins which
incorporate the spermidine-derived aminobutyl moiety as hypu-
sine. As described previously, this can be exploited to analyze and
quantify hypusination by metabolic labelling of cells using 3H-
labeled spermidine [40].
Briefly, 2,56106 U87-MG or G55T2 cells were seeded in
a 10 cm cell culture dish. 25 mCi 3H-Spermdin (Hartmann
Analytic) were added and cells were harvested after 48 hours.
200 mg of total protein were precipitated by adding one volume of
100% trichloric acid (TCA) to nine volumes of lysate and
incubation for 5 minutes at 220uC and 15 minutes at 4uC.
Proteins were spun down for five minutes at 160006g. Protein
pellets were washed twice with 1 ml of 10% TCA containing
1 mM spermidine and spermine followed by resuspension in
100 ml 1 N NaOH containing 1 mM spermidine and spermine
respectively. Proteins were reprecipitated by adding 1 ml of 10%
TCA, incubation for 30 minutes at 4uC and centrifugation. The
activity in the supernatant was measured with a liquid scintillation
analyzer (Tri-Carb 2900TR, PerkinElmer) and the washing steps
were repeated until no radioactivity .200 dps was detectable.
After resuspension of proteins in 100 ml 1 N NaOH, radioactivity
of total proteins was measured as described above.
Lentiviral Transduction
Small hairpin RNAs against human eIF-5A mRNA in
a lentiviral vector (pLKO.1-puro) were purchased from Sigma-
Aldrich (MISSION shRNA clones TRCN0000062551,
TRCN0000062552, TRCN0000062548, TRCN0000062549,
TRCN0000062550. Similar vectors expressing shRNAs against
DHS mRNA (Sigma-Aldrich) were a kind gift by Dr. Jan
Chemnitz (Heinrich Pette Institute, Hamburg). The packaging
plasmids pMDLg/pRRE (Gag/Pol), pRSV-Rev (Rev) and
phCMV-VSV-G (envelope) were used for production of lentiviral
particles in 293T packaging cells as described elsewhere [41].
Supernatants containing viral particles were passed trough
a 0.45 mM filter and applied to the target cells for 24 hours
supplemented with 8 mg/ml polybrene. For selection of trans-
duced G55T2 and U87-MG cells, cultures were grown in presence
of 2.5 mg/ml puromycin for two days.
Lentiviral gene ontology (LeGO) vectors [42] have been used to
express human wild type p53 (Accession number NM_000546) in
G55T2 cells [43]. Besides p53, the bicistronic vector expressed
a combined drug selectable fluorescent marker [44], consisting of
Cerulean fluorescent protein (cyan) and Puromycin N-acetyl-
transferase, conferring resistance to puromycin. The correspond-
ing control vector expressed the combined marker only. Maps of
both vectors are provided (see Figure S1).
Determination of Necrotic and Apoptotic Cells, Cell Cycle
Analysis and Detection of Senescence-associated b-
galactosidase Positive Cells
For measuring necrosis/apoptosis and cell cycle, 56105 cells
were seeded in 6 cm dishes and 50 mM GC7, 150 mM TMZ or
20 mM BCNU alone or TMZ/BCNU in combination with GC7
were added after 12 hours of preincubation. Cells were harvested
after 48 hours of incubation, and cell cycle or the sub-G1
population was analyzed by propidium iodide (PI) staining
followed by flow cytometry (FACSCalibur, Becton-Dickinson) as
described by Riccardi and Nicoletti [45]. Cell cycle analysis was
performed using the FlowJo software (Tree Star). The cleavage of
caspase-3 as a marker for apoptosis was determined by FACS
using a cleaved caspase-3 specific, PE-linked antibody (BD
Bioscience), after cells were incubated with GC7 as described
above and fixed with 2% paraformaldehyde and 90% methanol.
For detection of apoptotic cells by TUNEL assays, 16104 U87-
MG or G55T2 cells per well were seeded on a 4-well chamber
slide and incubated with 50 mM, 100 mM GC7 or vehicle for
72 hours. The assay was performed with the In Situ Cell Death
Detection Kit, POD (Roche) according to the manufacturers’
instructions. Senescence-associated activity of lysosomal b-galac-
tosidase was investigated as described in [46]. Microphotographs
of cells were taken with an Axiovert 25 microscope and an
AxioCam MRc camera (Zeiss) at 1006 or 3206magnification.
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Detection of Apoptosis by Annexin-V/Propidium Iodide
Staining
U87-MG and G55T2 cells were seeded in 10 cm cell culture
dishes (0.56106 per dish) and treated with 150 mM TMZ, 50 mM
GC7 or a combination of both as indicated above. Cells were then
harvested and stained with Annexin-V-FITC and PI (BD Bio-
science) according to the manufacturer’s instructions. Quantitative
analysis of viable, apoptotic and dead cells was performed by flow
cytometry, with 20.000 events acquired from each sample.
Statistics
Statistical analysis for immunohistochemistry was performed
using the SPSS software version 15. Patient age, gender, tumor
type (astrocytoma vs. oligodendroglioma), tumor grade and
immunohistochemical staining intensity were correlated. Compar-
Figure 1. eIF-5A, DHS and DOHH are expressed in gliomas of different grades. (A and B) DOHH and DHS expression significantly correlate
with tumor grade (mean staining intensity6 SEM; *:p,0.01 and **:p,0.001, respectively; two-sided non-parametric Kendall tau-b correlations). (C) In
the brain mainly large neurons (arrows) such as in the pyramidal layer of the cortex (left column) or in the brain stem (right column, arrows point to
neurons of the nuclei arcuati) were labelled. The scale bar represents 100 mm.
doi:10.1371/journal.pone.0043468.g001
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isons involving metric variables were analysed according to
Pearson whereas all ordinal scaled variables were compared using
the Kendall tau-b test. For other experiments we performed
unpaired two-tailed t-tests, using GraphPad Prism 5.01 (GraphPad
Software).
Ethics Statement
The immunohistochemical study was performed on archival
tissue that was processed and diagnosed in the Institute of
Neuropathology, University Medical Center Hamburg-Eppen-
dorf, Germany. According to the law for hospitals in Hamburg
(Hamburger Krankenhausgesetz), Germany, samples of closed
cases that were processed and investigated in a medical institution
may be used anonymously for research purposes by the same
institution without need for a separate written informed consent
from the patients.
Results
eIF-5A, DHS and DOHH are Overexpressed in Glioma
Tissue Samples with Different Grades and in
Glioblastoma Cell Lines
Using immunohistochemistry (IHC), we found elevated expres-
sion levels of DHS, DOHH and eIF-5A in 173 glioma samples
with different grades (Table S1). eIF-5A was demonstrated to be
overexpressed in all tumors (Figure 1A). This observation was
independent from tumor grading. The isoform eIF-5A2 was only
detected in one single tumor. Interestingly, DHS and DOHH
were significantly upregulated in glioblastoma samples compared
to tumors of grade I–III (Figure 1A, Table S2). To estimate the
expression of these proteins in normal brain, we performed IHC
on tissue from two healthy donors. As depicted in Figure 1C, the
anti-DOHH antibody immunolabelled neurons, oligodendroglia,
astrocytes, fibroblasts, endothelia, smooth muscle cells of vessels
and pituitary tissue whereas the other three antibodies did not
bind to normal astrocytes. In detail, DHS expression was detected
in neurons, ependyma, fibroblasts and pituitary. eIF-5A was also
found in neurons, ependyma and pituitary and additionally in
meningothelial cells, choroid plexus and some reactive astrocytes.
Notably, we could not detected eIF-5A expression in the majority
of the glia cells. The second isoform eIF-5A2 was present in
neurons, ependyma, meningothelial cells, fibroblasts, smooth
muscle cells and pituitary (Figure 1C). In order to establish an
in vitro model for further functional characterisation of the
hypusine modification in gliomas, we analysed the expression of
eIF-5A, eIF-5A2, DHS and DOHH in different cell lines.
Determination of mRNA and protein levels of eIF-5A, DHS
and DOHH in G55T2 and U87-MG cell lines showed over-
expression of eIF-5A and the two hypusine forming enzymes
compared to primary human astrocytes (Figure 2A. Overexpres-
sion of the eIF-5A2 isoform was detectable in G55T2, but not in
U87-MG cells. The expression level of all four analysed mRNAs
was highest in G55T2 cells, whereas in U87-MG cells it was not as
pronounced but statistically significant. These findings were
confirmed on protein level, however contrary to qPCR results,
DOHH protein levels seemed to be higher in U87-MG cells than
in G55T2 (Figure 2B).
Inhibition of DHS by GC7 Induces Antiproliferative Effects
in vitro
Based on this significant overexpression of the hypusine
associated proteins in gliomas and glioma cell lines, we asked
Figure 2. eIF-5A, DHS and DOHH are overexpressed in the glioblastoma cell lines G55T2 and U87-MG. (A) Expression levels of eIF-5A, -
A2, DHS and DOHH were analysed by qPCR (mean 6SD, n= 3; *:P,0.05; **:P,0.001 ) in primary normal human astrocytes (NHA) compared to G55T2
and U87-MG cell lines. SYBR green Ct values were normalized against GAPDH expression and calculated using the 22DDCT method. (B) Overexpression
of eIF-5A, DHS and DOHH was confirmed by immunoblotting with whole cell lysates (35 mg protein per sample).
doi:10.1371/journal.pone.0043468.g002
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whether hypusination inhibitors (HI) were able to inhibit the
proliferation of glioma cell lines in vitro. In a first set of
experiments we confirmed that the known DHS inhibitor GC7
inhibited the hypusine synthesis in vitro [47]. For this purpose we
used 2D-Western blotting of eIF-5A and 3H-Spermidin incorpo-
ration assays. Hypusin-containing eIF-5A can be distinguished by
2D-Western blot, since the non-hypusinated form is characterized
by a different (more acidic) isoelectric point compared to its
hypusinated counterpart. In the cell lines G55T2 and U87-MG,
the majority of eIF-5A is hypusinated, indicated by a single protein
spot (Figure 3A). The posttranslational hypusine modification of
eIF-5A can be prevented by treating cells with the spermidine
analogue GC7, which inhibits DHS by competitive replacement of
its native spermidine substrate. Treatment of glioblastoma cells
with GC7 in vitro resulted in a reduced amount of modified eIF-5A
(50% in G55T2 and 45% in U87-MG) indicated by a second,
more acidic eIF-5A spot in 2D-Western blot (Figure 3A). This was
verified by a lower rate of 3H-spermidine incorporation in G55T2
and U87-MG cells (Figure 3B). The inhibition of DHS with
increasing doses of GC7 showed a concentration-dependent
reduction of proliferation in glioblastoma cells (Figure 3C). The
effect of GC7 was already detectable after 48 h hours (data not
shown) with a ,50% reduction of cell proliferation at 50 mM
after 72 hours compared to untreated cells. Noteworthy, normal
human astrocytes showed no significantly reduced proliferation
within 72 hours with the lowest growth at 100 mM (73%
compared to untreated cells). We could not detect an increase of
apoptotic or necrotic cells by trypan exclusion (data not shown), no
effect on the sub-G1 fraction of PI stained cells and no increase of
caspase-3 positive cells (Figure 3D and E) or TUNEL positive cells
(data not shown) when cells were treated with GC7. GC7 treated
GBM cells showed morphological changes after two days
(Figure 3F). Interestingly, U87-MG cells became flattened or
round and detached. In contrast, G55T2 cells did not become
flattened. Instead they started to accumulate vesicles in the
cytoplasm.
Knock-down of eIF-5A and DHS Impairs Proliferation of
Glioma Cells in vitro
Since GC7 is a polyamine analogue, it may cause physiological
responses which cannot be attributed to the inhibited hypusine
formation. To exclude such drug-induced side-effects, DHS and
eIF-5A were knocked down by stable lentiviral expression of
shRNAs in G55T2 and U87-MG cells. A pool of four DHS
shRNA vectors could significantly reduce DHS expression on
mRNA and protein level (Figure 4A and B) and resulted in
morphological changes comparable to glioblastoma cells treated
with higher doses (50–100 mM) of GC7, although the effect in
G55T2 cells was less pronounced when directly compared to U87-
MG (Figure 4C). As expected, the proliferation was significantly
reduced to 30% for U87-MG (p,0.001) and 45% for G55T2
(p,0.001) compared to cells transduced with a scrambled shRNA
(Figure 4D). Knockdown of eIF-5A with four different shRNAs
resulted in a strong to moderate (U87-MG) or moderate to low
(G55T2) knockdown compared to cells transduced with a scram-
bled shRNA (Figure 4E). Both U87-MG lines (with strong or
moderate knockdown) show a significantly lower proliferation after
five days, whereas the achieved eIF-5A knockdown in G55T2 cells
was not sufficient to induce an antiproliferative effect (Figure 4F).
GC7 Treatment Induces Premature Senescence in U87-
MG Cells
Inhibition of hypusine formation has been reported to have an
effect on the cell cycle progression in some cell types, e.g. yeast
cells, murine neuroblastoma and erythroleukemia cell lines [48].
We could observe an increase of U87-MG cells in the G1-phase
from 53% to 92% and a reduction of cells in S- and G2-phase
(from 33% to 3% and 14% to 5% respectively) after treatment
with 100 mM GC7 (Figure 5A). This increase of cells in the G1-
phase and their morphology led us to the assumption that cells
enter a terminal cell cycle arrest, reminiscent of premature
senescence. Indeed, in a senescence-associated (SA) b-galactosi-
dase staining, GC7-treated U87-MG cells were positive. We
observed a 27-fold increase of SA-b-gal+ in GC7 treated cells
compared to mock-treated cells (Figure 5C and D). This
phenotype was supported by the observation that p21Waf1/Cip1,
one of the key regulators of the cell cycle, was strongly upregulated
15-fold (Figure 5B). This was accompanied by a 4-fold reduction of
phosphorylated AKT (an inhibitor of the p21Waf1/Cip1 mediated
antiproliferative effect). In contrast, no senescent phenotype could
be observed in G55T2 cells. Those cells were negative for the SA-
b-galactosidase staining and the G1-population increased only
from 38% to only 50%, whereas the S- and G2-populations
dropped from 44% and 14% to 35% and 10% respectively. In
contrast to U87-MG cells, p53 was upregulated, but p21Waf1/Cip
was not detectable with or without GC7 in G55T2 cells and no
change in phosphorylated AKT occurred.
Restoration of p53wt Enables Premature Senescence in
G55T2 Cells after DHS Inhibition
In order to further investigate the role of p53 in hypusine-
dependent induction of senescence we expressed wild type p53 in
G55T2 cells. Transduction of G55T2 cells with p53 lead to cell
death of the transduced population (data not shown). This p53wt+
population was reduced 10-fold within eight days post trans-
duction, whereas cells transduced with an empty control vector
remained viable (Figure 6A), indicating p53-sensitivity of the p53-
mutated G55T2 cells. Treatment with 100 mM GC7 for 72 hours,
starting 24 hours post transduction, lead to an increase of cells in
premature senescence as assayed by SA-b-galactosidase staining
Figure 3. Effect of GC7 on proliferation, hypusine status and viability in G55T2 and U87-MG cells. (A) Cells were incubated with 50 mM
GC7 or vehicle for 48 hours. The effect of GC7 on eIF-5A hypusination was determined by a change of the pI of eIF-5A, visualized by 2D-Western blot
using an antibody against eIF-5A (25 mg total protein, pH 4–7 first dimension strips). (B) To verify reduced hypusination, cells were co-incubated with
GC7 and 25 mCi 3H-spermidine. 200 mg of total cellular proteins were precipitated with 10% TCA and excessive radioactivity was removed by
washing. The protein pellet was resuspended in 1 N NaOH and the activity of 3H, incorporated into hypusine, was measured. (C) Normal human
astrocytes (NHA), G55T2 and U87-MG cells were treated with the indicated concentrations of GC7 for 72 hours. Viable cells were counted by trypan
blue exclusion and data are expressed as relative cell numbers compared to mock treated cells (mean6SD, n= 6). Significantly different cell numbers
compared to controls are indicated by asterisks (*:P,0.05; **:P,0.001). (D) U87-MG and G55T2 cells were treated with 50 mM GC7 (black area) or
water (dotted area) for 72 hours, fixed in 70% ethanol and stained with PI. Apoptotic/necrotic (sub-G1) populations were determined by FACS
analysis after PI staining. (E) U87-MG and G55T2 cells were treated with 50 mM GC7 (gray area) or water (dashed area) and stained with antibodies
against cleaved caspase-3 or isotype control (dotted area) to determine the rate of ongoing apoptosis upon treatment. (F) Microphotograph of mock
and GC7 treated U87-MG and G55T2 cells after five days of drug treatment. The photos were taken at x100 magnification. Arrows mark examples of
morphologic changes upon treatment. Each bar represents 10 mm.
doi:10.1371/journal.pone.0043468.g003
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(Figure 6B and C; 4% untreated p532 vs. 30% p53wt+/+GC7).
However, even in the absence of GC7, a significant fraction of the
p53-transduced cells was SA-b-galactosidase+ compared to p53-
cells (with or without GC7). Nevertheless, treatment with GC7
increased the amount of SA-b-galactosidase+ cells significantly (8%
vs. 30%). Additionally, the application of GC7 for 72 hours
increased the expression of p21 in p53wt+ cells, whereas in cells
transduced with the empty vector, p21 expression remained low
(Figure 6D). As observed in U87-MG cells, induction of
senescence and p21 up-regulation was accompanied by a reduction
of phosphorylated AKT.
Co-treatment of Glioblastoma Cells with TMZ/BCNU and
GC7 has an Additive Antiproliferative Effect
As expected, U87-MG and G55T2 cells were both susceptible
to treatment with TMZ and BCNU and have shown a dose
dependent reduction of proliferation, with the exception of U87-
MG cells at 150 mM TMZ (Figure 7A). Both cell lines reacted
similar to BCNU with cell numbers ,50% compared to controls
after 72 hours treated with 50 mM BCNU. Clearly, the cell line
G55T2 was more sensitive to TMZ (Figure 7A). 72 hours after
administration of 150 mM TMZ, cell numbers were 50% less as
compared to controls, whereas in U87-MG cells even 200 mM
could reduce proliferation to only about 70% (Figure 7A). To rule
out a potential effect of alkylating drugs on the hypusine pathway,
we analysed the hypusine status of eIF-5A in cells treated with
150 mM TMZ or 20 mM BCNU compared to cells treated with
50 mM GC7. As described before, inhibition of DHS results in
accumulation of unhypusinated eIF-5A. As shown in Figure 7B,
TMZ or BCNU had no comparable effect and no accumulation of
non-modified eIF-5A was detectable.
Co-treatment of G55T2 cells with 150 mM TMZ and 10 mM
GC7 did not result in an enhanced antiproliferative effect, but co-
treatment with 50 mM GC7 resulted in a significant (p,0.001)
reduction of proliferation to 28% as compared to cells treated with
TMZ alone (Figure 7C). Co-treatment with 20 mM BCNU and
50 mM GC7 yielded a similar result with a reduction of cell
number to 44% as compared to cells incubated with 20 mM
BNCU alone (p,0.001). The reaction of U87-MG cells was
slightly different, with a cell number of 70% (concurrent treatment
with 20 mM BCNU and 10 mM GC7; p,0.05) and 50% (20 mM
BCNU and 50 mM GC7; p,0.001) as compared to cells
incubated with solely BCNU. Co-treatment with TMZ and GC7
yielded a lower proliferation rate comparable to G55T2 cells (56%
with 10 mM GC7 and 34% with 50 mM GC7 respectively). In this
study, treatment of GBM cells with alkylating agents for 72 hours
resulted in cell cycle arrest in G2-M phase (TMZ data not shown)
with a minor increase of the sub-G1 population in case of BCNU
treatment (data not shown) and an accumulation of hyperploid
(.4n) cells, mimicking the results described previously [49–52]
(Figure 7D). Since inhibition of hypusine synthesis lead to rise of
the G1-fraction and TMZ/BCNU treatment to G2-M arrest,
a combination of those agents caused a mixed phenotype within
72 hours of incubation. The fraction of cells with haploid DNA
content in double treated cells was smaller or equal compared to
control cells, but higher compared to BCNU treated ones,
reflecting the increase in the G1-population caused by GC7. The
G2-M population was equal in cells incubated with BCNU alone
or together with GC7. However, in BCNU/GC7 double treated
cells, the poly-n population was reduced considerably compared to
single treated cells (Figure 7D). Although GC7 alone was not able
to induce apoptosis in our cellular model, we wanted to explore
a possible proapototic effect in TMZ-stressed cells. Therefore, we
analysed the accumulation of early apoptotic and late apoptotic/
dead cells by Annexin-V/PI double staining in GBM cells after
single treatment with TMZ, GC7 or a combination of both
compounds (Figure 8A–B). As depicted in Figure 8 treatment with
TMZ and GC7 alone or in combination did not result in
a significant induction of apoptosis neither in U87-MG (Figure 8A)
nor in G55T2 cells (Figure 8B).
Discussion
The pro-proliferative properties of eIF-5A and antiproliferative
effects of inhibited hypusine formation have been firmly estab-
lished in the past (e.g. by Park et al. [53]). To evaluate a possible
role of eIF-5A and the hypusine synthesizing enzymes in glioma,
we analysed samples from 173 glioma patients. We found a general
eIF-5A overexpression in tumor cells and an upregulation of DHS
and DOHH in glioblastomas compared to tumors of grade I–III.
These findings may indicate a role for hypusinated eIF-5A in the
formation or progression of gliomas, especially in glioblastomas.
This hypothesis is substantiated by the finding that in samples of
two non-glioma patients, eIF-5A, eIF-5A2 and DHS expression
was mainly detectable in persisting neurons, ependymal and some
other brain tissues, but rarely or not at all in astrocytes. This
underscores the role of hypusinated eIF-5A in transformation or
propagation of tumor cells, since glioblastomas are possibly
derived from progenitors along the neural stem cell-astrocytic
axis or de-differentiated astrocytes [54]. Further, more recent gene
expression studies have revealed that glioma-patients with a high
expression of eIF-5A have a lower probability of survival,
compared to patients with an intermediate expression (National
Cancer Institute REMBRANDT database www.caintegrator.nci.
nih.gov/rembrandt; p = 0.043; mean of all reporters; Figure S2).
Additionally, in a dataset available through ‘‘The Cancer Genome
Atlas Research Network’’, two transcripts of eIF-5A are over-
expressed in GBM (p = 0.0344 and p = 0.000181) [5]. The main
transcript of DHS is upregulated as well (p = 0.0408). In contrast,
the expression of DOHH is not altered. However, two miRNAs
putatively targeting the DOHH mRNA are strongly down-
regulated in tumors (both p,0.0001). That indicates the biological
significance of the hypusine modification systems in glioblastoma.
Figure 4. Knockdown of DHS mRNA in U87-MG and G55T2 cell lines by gene specific shRNAs. (A) Relative DHS-mRNA expression in
G55T2 and U87-MG cells after lentiviral transduction with a scrambled shRNA (G55T2-ctrl and U87 ctrl) or DHS-specific shRNA pools normalized
against GAPDH (mean6SD, n= 3). (B) Immunoblot (30 mg total protein per sample) against DHS and b-Tubulin in G55T2 and U87-MG cells after
lentiviral transduction with a scrambled shRNA (G55T2-ctrl and U87-ctrl) or DHS-specific shRNAs (G55T2 DHS-sh and U87 DHS-sh) after two days of
puromycin selection. (C) Glioblastoma cell lines after transduction with a scrambled control shRNA or an shRNA-pool against DHS (1006
magnification) with 100 mm scale bars. (D) Proliferation of transduced cells measured by trypan blue exclusion over five days. Significantly different
cell numbers or DHS expression compared to controls are indicated (*:P,0.05; **:P,0.001). (E) Immunoblot results of U87-MG and G55T2 cells after
transduction with a scrambled control shRNA (ctrl) or four different shRNAs against eIF-5A (30 mg total protein). Transduced cells were selected by
incubation with puromycin for two days, cell lysates were obtained seven days post-selection. (F) Proliferative capacity of transduced cells with strong
(A1-sh2 for U87-MG and A1-sh1 for G55T2) or moderate (A1-sh3 for U87-MG and A1-sh2 for G55T2) eIF-5A knockdown was determined by trypan
blue exclusion cell counting over five days. Significantly different cell numbers compared to controls are marked by an asterisk (*:p,0.05).
doi:10.1371/journal.pone.0043468.g004
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To evaluate the possible role of functional eIF-5A as a potential
therapeutic target in glioblastomas, we treated tumor derived cell
lines with GC7, a well established specific inhibitor of desoxyhy-
pusine synthase (DHS), and compared its antiproliferative effect to
treated primary astrocytes. Clearly, GC7 reduced the proliferation
of glioblastoma cells significantly and caused changes in cell
morphology. The effect of GC7 on the two glioblastoma cell lines
analysed in this study appears to be rather cytostatic than
Figure 5. Induction of cell cycle arrest and cellular senescence by GC7. GC7-treatment of U87-MG and G55T2 cells leads to a higher
proportion of cells in G1-cell cycle phase, upregulation of p21
Waf1/Cip1, downregulation of phospho-AKT and activity of senescence associate b-
galactosidase. (A) After incubation cells with 100 mM GC7, the cell cycle profile was compare to untreated cells by PI staining and FACS analysis. (B
and C) Total protein lysates (35 mg) of G55T2 and U87-MG cells after treatment with 100 mM GC7 (duplicates) or water were immunoblotted for p53,
p21Waf1/Cip1, phospho-AKT, AKT and b-tubulin. Signals were quantified after normalization against b-tubulin. (D and E) Microphotograph at x100
magnification of mock and GC7 treated U87-MG cells after SA-b-galactosidase assay. Scale bars represents 100 mm. Quantification of SA-b-gal+ cells
(triplicates, 200 cells per sample were counted; n.d. = no SA-b-gal+ cells detected).
doi:10.1371/journal.pone.0043468.g005
Figure 6. Restauration of p53 in G55T2 cells leads to increased premature senescence by DHS inhibition. (A) Empty vector- and p53-
transduced G55T2 populations were monitored by FACS, 4 and 8 days post transduction. (B and C) GC7 and mock treated G55T2 cells +/2 p53wt
were stained for SA-b-galactosidase activity. Microphotographs were taken at x100 magnification. Scale bars represents 100 mm. SA-b-gal+ cells were
determined in triplicates, 200 cells per sample were counted. (D) Expression of p21Waf1/Cip1, phospho-AKT, AKT and b-tubulin in GC7 treated G55T2
cells +/2 p53wt was analysed by immunoblotting.
doi:10.1371/journal.pone.0043468.g006
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cytotoxic. Strikingly, in U87-MG cells we could identify premature
senescence as a potential mechanism of observed reduction in cell
growth. U87-MG cells are positive for senescence-associated b-
galactosidase and upregulation of the p53-downstream effector
p21Waf1/Cip1 (a cyclin dependent kinase inhibitor and cell cycle
regulator) underlines the manifest G1-cell cycle arrest in those cells.
The nature of a senescent phenotype is complex and depends on
the cellular context as well as the senescence-inducing stimulus
[55]. p21Waf1/Cip1 expression can be regulated in a p53 dependent
manner and it is a key regulator of senescence [56]. Since the U87-
MG cells have deleted p16 and p14ARF [57], which are also
important regulators of senescence, we can assume that the
observed senescence phenotype relies on p21 as major regulator.
This finding is reinforced by the observed reduction of pAKT in
GC7-treated U87-MG cells. Phosphorylated AKT has been
described as an inhibitor of p21Waf1/Cip1 and its reduced activity
is likely to contribute to the p21Waf1/Cip1 mediated senescence [58].
In contrast to above findings, G55T2 cells, susceptible to GC7 as
well, showed no signs of senescence. Since these cells exhibit
mutated p53, the downstream signal transduction does not lead to
p21Waf1/Cip1 expression. These cells lack p16 and p14ARF as well
[57], and the lack of these two key regulators and the absence of
active p53 impedes the ability of G55T2 cells to induce premature
senescence. The importance of the p53/p21Waf1/Cip1 regulatory
axis for GC7 induced senescence becomes even more apparent
after reintroduction of wild type p53 into G55T2 cells. These cells
show a senescence phenotype when treated with GC7, whereas
cells transduced with a control vector do not. This sheds more light
on the connection between p53 and eIF-5A which has been
established previously by Li et al. [59] as well as Rahman-Roblick
et al. [60]. Rahman-Roblick et al. revealed an upregulation of eIF-
5A expression after induction of p53-dependent cell death. Li et al.
demonstrated an increase of p53 level (and expression of some of
its target genes, like p21 and Mdm2) upon endogenous over-
expression of eIF-5A. However, they did not confirm the hypusine
status of the exogenous eIF-5A, which can remain largely
unmodified if not complemented by an endogenous overexpres-
sion of DHS [55]. Thus, it remains unclear if an overexpression or
the accumulation of non-hypusinated eIF-5A plays a role in p53-
activation. Our results indicate the latter, since GC7-treated cells
quickly accumulate non-modified eIF-5A. Our results highlight
the role of p53 in eIF5A depend regulatory mechanisms. Further,
we could demonstrate a connection of DHS inhibition, accumu-
lation of non-modified eIF-5A, cell cycle arrest and induction of
p53-dependent premature senescence. These cells show a senes-
cence phenotype when treated with GC7, whereas cells trans-
duced with a control vector do not. These observations underscore
that inhibition of functional eIF-5A also regulates p53-indepen-
dent processes leading to a decrease in proliferation and growth
retardation. This might be of great impact for the treatment of
p53-defective glioblastomas. Importantly, GC7 had no notable
effect on proliferation, viability or morphology of astrocytes.
Since GC7 is a polyamine analogue, it probably affects other
polyamine dependent cellular processes at a certain concentration.
The use of non-spermidine related DHS inhibitors (e.g. CNI-1493)
could help to circumvent these off-target effects [61]. To exclude
such side effects as primary mode of GC7, we knocked down DHS
by stable expression of a shRNA-pool against DHS mRNA in
glioblastoma cells. DHS knockdown by a pool of four different
shRNA resulted in a significant reduction of cell growth and
a phenotype, similar to cells incubated with GC7. Knockdown of
eIF-5A, the target of DHS mediated hypusine synthesis only
yielded a moderately reduced proliferation. This contrast to cells
with reduced DHS activity could be explained in two ways. (i) eIF-
5A is highly expressed in GBM cell lines, thus the transduced
shRNAs against its mRNA are not able to convey a knockdown to
a level that is needed to achieve a more pronounced effect on the
cells. However, this contrasts with our finding that GBM cells with
Figure 7. Co-treatment of glioblastoma cells with alkylating agents and GC7 has an additive antiproliferative effect. (A) G55T2 or
U87-MG cells were treated with TMZ (150 mM and 200 mM) or BCNU (10 mM and 50 mM) for 72 hours. Cells were analyzed by trypan exlusion and
automated cell counting. (B) The direct effect of alkylating drugs on the synthesis of hypusinated eIF-5A was investigated by treating cells with TMZ
or BCNU and comparing the modification state of eIF-5A to GC7 treated cells by 2D-Western blot against eIF-5A. (C) Cells were treated with BCNU/
TMZ alone or together with two GC7 concentrations. Effects on the proliferative capacity of treated glioblastoma cells were measured by trypan blue
exclusion after 72 hours. Significantly different cell numbers compared to controls are indicated by asterisks (*:P,0.05; **:P,0.001). (D) The influence
of vehicle, TMZ/BCNU single and TMZ/BCNU and GC7 co-treatment on the cell cycle of U87-MG cells was evaluated by PI staining and subsequent
FACS analysis.
doi:10.1371/journal.pone.0043468.g007
Figure 8. Effects of a combination of GC7 with TMZ on induction of apoptosis. (A) G55T2 or (B) U87-MG cells were treated with TMZ
(150 mM) and/or GC7 (50 mM) for 72 hours.No significant cooperative effects of both drug in induction of apoptosis have been detected. Fractions of
viable, early apoptotic and dead cells were assayed by an Annexin-V/PI double staining and FACS analysis (no significant differences; p.0.05 for all
experiments).
doi:10.1371/journal.pone.0043468.g008
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moderate and high knockdown of eIF-5A show no difference in
proliferation. (ii) Unmodified eIF-5A is still present in the cell when
DHS is inhibited or knocked down. This form of eIF-5A was
shown to have proapoptotic properties, which contribute to the
antiproliferative effect of DHS inhibition [50,62]. Although we
could not observe apoptosis in our experiments, this may depend
on experimental settings or tissue origin of cells. In addition we
cannot exclude other antiproliferative effects of non-hypusinated
eIF-5A.
Treatment of glioblastoma patients with DNA damaging agents
such as BCNU or TMZ is the current standard of adjuvant
therapy after surgical removal of GBM. Thus we were interested
in the potential of DHS inhibition in enhancing TMZ/BCNU
mediated antiproliferative effects. The G2/M arrest (resulting in
senescence and/or apoptosis, depending on the experimental
setup) induced by TMZ has been studied in the past [63,64]. Our
results suggest an additive effect of combined TMZ/BCNU and
GC7 treatment, indicated by improved reduction in proliferation.
This is also reflected by the cell cycle of treated cells, which show
a combination of GC7 induced G1- and TMZ/BCNU character-
istic G2/M-arrest and accumulation of .4n cells. Thus we
speculate that the enhanced antiproliferative effect of a combina-
tion therapy is elicited by simultaneous cell cycle inhibition at G1/
S phase and G2/M phase checkpoints. TMZ and BCNU have no
effect on the hypusine status of eIF-5A, hence the combination of
alkylating agents and DHS inhibitors would provide a two-tier
approach in engaging GBM cells. Despite the involvement of eIF-
5A in apoptotic processes in various cancer models, we could not
confirm such role in GBM cells. Also in TMZ-stressed cells, we
could not observe any proapoptotic effect after inhibition of
hypusination, indicating that eIF-5A and its hypusine modification
have a role in proliferation control rather than in regulation of
apoptosis in GBM cells.
Taken together, these data establish an important role for eIF-
5A and the hypusine synthesizing enzymes in proliferation of
glioblastoma cells. We also showed, in a proof of principle
approach that the inhibition the DHS enzyme might serve as an
option to reduce growth of GBM cells. However, more in depth
studies and the design of DHS inhibitors, which are more suitable
for in vivo applications, are needed. Although eIF-5A, DHS and
DOHH are highly conserved and likewise expressed in healthy
tissues, their overexpression in aggressive astrocytomas and the
enhanced responsiveness of GMB cells compared to normal
astrocytes render these protein potential therapeutic targets in this
intracranial neoplasm. Further, eIF-5A and the hypusine synthesis
pathway are highly conserved in eukaryotes [65]. This eventually
reduces the probability of tumor cells to circumvent the inhibition
of hypusine synthesis.
Supporting Information
Figure S1 Schematic representation of the lentiviral
vector expressing human wild type p53 and control
vector, drawn as integrated provirus. A PCR fragment of
p53 cDNA has been cloned into the multiple cloning site of
LeGO-iCer2-Puro+ (EcoRI and NotI) and verified by sequencing.
Vector elements (not drawn to scale): SIN-LTR, self-inactivating
long terminal repeat; Y, packaging signal; RRE, rev-responsive
element; cPPT, central polypurine tract; SFFV, Spleen focus-
forming virus enhancer/promoter; wt p53, cDNA coding for
human wild-type p53; IRES, internal ribosome entry site of the
Encephalo myocarditis virus; Cerulean, a cyan fluorescent protein;
2A, self cleaving peptide of Porcine Teschovirus-1 (P2A); PuroR,
codon optimized cDNA of puromycin N-acetyltransferase (puro-
mycin resistance); wPRE, Woodchuck hepatitis virus post-
transcriptional regulatory element.
(DOC)
Figure S2 Kaplan–Meier survival plots show the surviv-
al of glioma patients with differential expression of eIF-
5A. Patiens with upregulation of eIF-5A (red line; n = 82) and
patients with intermediate expression (yellow; n = 241) are shown.
Log-rank p value (upregulated vs. intermediate, mean of all
reporters): 0.0433240981. Data obtained from National Cancer
Institute REMBRANDT database (https://caintegrator.nci.nih.
gov/rembrandt).
(DOC)
Table S1 Raw data of the immunostained TMAs. TMAs
were stained with anti-eIF-5A, -A2, DHS and DOHH antibodies.
Staining intensities were quantified in 4 grades (0: none, 1: slight
staining in up to 20% of cells, 2: moderate or strong staining in up
to 50% of cells, 3: moderate to strong staining of .50% of cells)
and only tumor cells were assessed. Tumortypes are 1 = astrocy-
tomas and 2 = oligodendrogliomas. Grade represents the WHO
glioma grade. Sex is coded as follows: 1 = female; 2 = male. Age is
given in years. Localisation is coded: 1 = frontal lobe; 2 = temporal
lobe; 3 = central; 4 = occipital cortex; 5 = cerebellum; 6 = spinal
cord; 7 = opticus.
(DOC)
Table S2 Mean staining intensity of DHS and DOHH
immunolabelled TMAs with SEM.
(DOC)
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